Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales

Sarepta Therapeutics, Inc. (SRPT) reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks Consensus Estimate of$1.87. However, the reported figure was significantly higher than the year-ago period’s 47 cents due to higher product sales.The loss included depreciation and amortization costs and stock-based compensation expenses. The adjusted EPS in the quarter was $1.90 compared with 82 cents in the year-ago period.Sarepta recorded total revenues of$658.4 million, up 66% year ...